In vitro susceptibility of TB- and MDR-TB-strains against linezolid at a local center in Berlin/Germany

T. Weiss, N. Schönfeld, R. Otto-Knapp, L. Bös, G. Bettermann, M. Harald, R. Holger, B. Torsten (Berlin, Germany)

Source: Annual Congress 2013 –Diagnostic features of tuberculosis I
Session: Diagnostic features of tuberculosis I
Session type: Thematic Poster Session
Number: 2777
Disease area: Respiratory infections

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Weiss, N. Schönfeld, R. Otto-Knapp, L. Bös, G. Bettermann, M. Harald, R. Holger, B. Torsten (Berlin, Germany). In vitro susceptibility of TB- and MDR-TB-strains against linezolid at a local center in Berlin/Germany. Eur Respir J 2013; 42: Suppl. 57, 2777

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Clinical experience of clofazimine in the treatment of MDR-TB
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013


Current status of fluoroquinolone use for treatment of tuberculosis in Korea
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013

Active drug-safety monitoring and management for tuberculosis patients treated with bedaquiline and linezolid, Belarus – 2014-2016
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016

Active pharmacovigilance for multidrug-resistant tuberculosis patients treated with Linezolid, Belarus – 2014-2015
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015


Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety
Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline
Year: 2016



Prevalence of aminoglycoside resistance among different MDR tuberculosis cases in Ukraine
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013


Study on drug sensitivity patterns in tuberculosis in tertiary care in Mumbai
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016

Linezolid in the treatment of patients with MDR TB and XDR TB
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013


Administration of linezolid, bedaquiline and imipenem in treatment of patients with extensively drug-resistant tuberculosis
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015

Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016

Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)
Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights
Year: 2013

Prevalence of fluoroquinolon-resistance among different MDR tuberculosis cases in Ukraine
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013


Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016


Efficiency of MDR-TB therapy with the use of thioureidoiminomethylpyridinii perchlorate
Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments
Year: 2016


Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016

Implementation of rapid drug-susceptibility testing for patients at high risk of multidrug-resistant tuberculosis in Cambodia
Source: Annual Congress 2013 –Diagnostic features of tuberculosis I
Year: 2013

Frequency of rifampicin resistance in re-treatment cases of pulmonary tuberculosis using Gene-Xpert in a tertiary care hospital tuberculosis clinic
Source: International Congress 2015 – WHO guidelines in TB and clinical practice
Year: 2015


Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia)
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015

Efficacy of moxifloxacin in TB resistant to isoniazid
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015


Study of prevalence of drug resistance in tuberculosis (TB) patients attending a tertiary care hospital at Mumbai
Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis
Year: 2016